The software titan's fiscal Q2 earnings report, which covers the selling period through late December, just revealed strong sales growth and improving profitability into 2022. CEO Satya Nadella and his team also issued a bullish short-term outlook that implies continued high demand for tech products in both the consumer and enterprise niches. Executives issued an investor presentation along with their earnings press release and conference call that help explain why Microsoft is so optimistic about fiscal 2022 and beyond. Read More...
Motley Fool
What’s Next For Novavax Stock?
Despite seeing losses of more than 50% this year and severely underperforming the market, Novavax (NASDAQ: NVAX) stock might not be finished falling. In late December 2021, the World Health Organization granted another emergency use listing for its coronavirus vaccine, but, much to the chagrin of shareholders, it failed to stop the stock’s tumble. While it might not be enough to stem the stock’s losses immediately, Novavax will report its fourth-quarter earnings either at the end of February or at the start of March.
Add Comment